Antiangiogenic therapy for ischemic retinopathies. - Wikidata - wikimedia - TriplyDB

Antiangiogenic therapy for ischemic retinopathies.

Antiangiogenic therapy for ischemic retinopathies.

http://www.wikidata.org/entity/Q34295974

about

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy Tissue factor induces VEGF expression via activation of the Wnt/β-catenin signaling pathway in ARPE-19 cells Identification of novel drug targets for the treatment of diabetic retinopathy.In vivo adaptive optics microvascular imaging in diabetic patients without clinically severe diabetic retinopathy Ubiquitin carboxyl-terminal esterase L1 promotes proliferation of human choroidal and retinal endothelial cells.Tissue factor with age-related macular degeneration.Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice.Dietary Compound Chrysin Inhibits Retinal Neovascularization with Abnormal Capillaries in db/db Mice.In vitro and ex vivo retina angiogenesis assays.Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy.Animal models of ocular angiogenesis: from development to pathologies.Characterization of Vitreous and Aqueous Proteome in Humans With Proliferative Diabetic Retinopathy and Its Clinical Correlation.Clinical pharmacology of intravitreal anti-VEGF drugs.The Role of mf-ERG in the Diagnosis and Treatment of Age-Related Macular Degeneration: Electrophysiological Features of AMD.Intraocular Hemorrhage due to use of Sildenafil in a Patient with Diabetes Age-Related Macular Degeneration: Pathogenesis, Genetic Background, and the Role of Nutritional Supplements

P2860

Q28067341-0A9D3D5C-7B07-4773-A966-5B4C8BF9E93B Q28828849-0636DA5D-6624-4DA6-BE35-D724D078DB3B Q31134280-0B9C2AD6-3ED5-4318-AF24-4B06585B08ED Q35136619-7B548E04-632F-4BF4-B373-1A152D00FDA1 Q35558017-0685E512-368B-4CFA-8EAF-C8D0890647C4 Q36358685-555834FB-D9C5-4076-A923-7B227D20936B Q37054876-7CEB2D72-8E39-497E-AB71-16370B228FE4 Q37535413-6FED07B9-9AD0-4FB1-8EFA-98107CF2ADD8 Q38152261-DE3DB34A-C7A9-47FE-AF14-184D2A1522B0 Q38153731-35492575-D62F-4963-B928-0927FD2FC73A Q39455385-B07A14EC-48C4-4A50-9624-C448BB9C4721 Q41897708-5D8032B2-8631-4F31-947B-7C8DCBF1A0E5 Q48109878-80B21DF3-BE17-4BE1-A8B4-B9CFC6CF80CF Q53412654-63161DC8-7869-42C4-A68D-ECF31D2668F0 Q58597196-B01BF49E-5A20-49AD-85BA-5F29BA4E4A8A Q59055823-ED5D7490-5574-4691-B110-E27FEC6E566E

P2860

Antiangiogenic therapy for ischemic retinopathies.

http://www.wikidata.org/entity/Q34295974

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Antiangiogenic therapy for ischemic retinopathies.

@ast

Antiangiogenic therapy for ischemic retinopathies.

@en

Antiangiogenic therapy for ischemic retinopathies.

@nl

type

label

Antiangiogenic therapy for ischemic retinopathies.

@ast

Antiangiogenic therapy for ischemic retinopathies.

@en

Antiangiogenic therapy for ischemic retinopathies.

@nl

prefLabel

Antiangiogenic therapy for ischemic retinopathies.

@ast

Antiangiogenic therapy for ischemic retinopathies.

@en

Antiangiogenic therapy for ischemic retinopathies.

@nl

P1433

Q34295974-9C703F6C-B509-4EE9-BE0E-C852E0C372AC

P1476

Q34295974-AE74F325-1E3D-4608-B95F-9A6AACCEF9B3

P2093

Q34295974-29BAA119-BEB0-499A-B8B7-C9227C71E92C

Q34295974-3B3E1284-8A7B-4284-9601-6B8ECC5A6D73

Q34295974-411C76A1-36ED-4058-9876-85C911BF63D6

Q34295974-E41651BE-D0C9-4E55-940C-7BB5C850DB9A

P2860

Q34295974-02B584BB-5F63-4EE2-A036-689EA6234035

Q34295974-03F7C52C-46C5-481E-B898-D70884945A11

Q34295974-076A077F-7C9D-488E-8B12-832E436EBB06

Q34295974-09120C7C-B717-4757-8240-D11725E3996C

Q34295974-0B66E399-EFAB-4840-AF25-4DC3EFB83730

Q34295974-0BBE5127-1151-4F76-B85F-1EA55FAD9C5F

Q34295974-0C4BAE10-EA69-4566-A75B-4EC45A404B13

Q34295974-0C5A8B62-0D6D-446F-BBE3-6EEEFC73ACFB

Q34295974-0F54B55B-267E-4FDC-B03A-DC92A6BCB4A4

Q34295974-1068DCE5-FB17-484D-BCDA-48B87C8BA3C0

P304

Q34295974-8598B2F9-97FA-4200-85C1-FFF2FCB699C5

P31

Q34295974-17C072CB-F779-46D6-9ACC-49BE46B18B62

P356

Q34295974-0AC3B4E3-66AC-45C3-A9A6-90680DAF99DD

P433

Q34295974-E9342E06-6916-4698-A1DA-FA688E7F1337

P478

Q34295974-30CB7B4B-8678-4D19-B7F5-CBB3C90C9F32

P577

Q34295974-CBB20C12-888F-4808-A072-5F3243BA662A

P5875

Q34295974-907573E2-2DE5-4BC0-93F9-A7C18C38ACC6

P698

Q34295974-7E462746-2CF2-4D91-A8C5-619418F23A9A

P932

Q34295974-2EB81036-2C98-46C9-9D2F-C03BB1AA2A8B

P356

CSHPERSPECT.A006411

P1433

Cold Spring Harbor Perspectives in Medicine

P1476

Antiangiogenic therapy for ischemic retinopathies.

@en

P2093

Jennifer K Sun

http://www.w3.org/2001/XMLSchema#string

Lloyd Paul Aiello

http://www.w3.org/2001/XMLSchema#string

Motasem Al-Latayfeh

http://www.w3.org/2001/XMLSchema#string

Paolo S Silva

http://www.w3.org/2001/XMLSchema#string

P2860

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

VEGF-Trap: a VEGF blocker with potent antitumor effects.

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8

Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19

Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy

A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein

P304

a006411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1101/CSHPERSPECT.A006411

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225276791

http://www.w3.org/2001/XMLSchema#string

P698

22675660

http://www.w3.org/2001/XMLSchema#string

P932

3367538

http://www.w3.org/2001/XMLSchema#string